A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.

2002135 citationsJournal Article

Authors

Alan K. Matsumoto · Johns Hopkins University

Augustin Melian · Arthritis and Rheumatism Associates

David R. Mandel · Arthritis and Rheumatism Associates

Harris McIlwain · Arthritis and Rheumatism Associates

David Borenstein · Arthritis and Rheumatism Associates

Peng Zhao · Arthritis and Rheumatism Associates

Christopher R. Lines

Abstract

In this study, etoricoxib 90 mg once daily was more effective than either placebo or naproxen 500 mg twice daily for treating patients with RA over 12 weeks. Etoricoxib 90 mg was generally well tolerated in patients with RA.

Topics & Keywords

Inflammatory mediators and NSAID effects Drug-Induced Adverse Reactions Rheumatoid Arthritis Research and Therapies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: PubMed

Volume 29, Issue 8, pp. 1623-30

Field-Weighted Citation Impact: 10.46